מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – For patients co-infected with HIV and the hepatitis C virus (HCV), daily administration of interferon alpha-2b is more than twice as effective as the traditional three times/week regimen in suppressing HCV loads. This finding was presented Friday at the Infectious Diseases Society of America's 39th annual meeting in San Francisco.
A total of 180 such patients were randomly assigned to daily or thrice-weekly dosing with 3 mIU interferon-alpha-2b, plus 800 mg/day oral ribavirin. More than 85% of subjects were also using highly active antiretroviral therapy.
At 12 weeks, 31.6% of patients receiving daily injections had reductions in blood HCV levels to below the level of detection, compared with 12.1% of those receiving interferon three times/week.
"Because daily administration is more effective than the standard, this suggests that recently approved pegylated interferon will be a better choice for this population," presenter Dr. Mark Sulkowski, of Johns Hopkins University in Baltimore, told Reuters Health. With the new preparation, he said, injections would be once a week, but blood interferon levels would be maintained at a level similar to those observed after once-daily injection.
"An added plus was that neither regimen appeared to adversely affect any HIV parameters," Dr. Sulkowski added.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!